Skip to content
Clinical Trials – home
Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Verified siteFast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Endometrial cancer is a disease that starts in the lining of the uterus. In some patients the tumor is classified as mismatch repair proficient (MMRp), meaning the cells’ normal DNA‑repair system is still working. The study focuses on people whose disease is advanced or has come back after earlier treatment.

The investigational medicine being tested is mocertatug rezetecan. It is given together with a doctor‑chosen form of immune checkpoint inhibition, either the drug dostarlimab or the drug pembrolizumab. These immunotherapy medicines help the body’s immune system recognize and attack cancer cells. The trial compares this combination with using the immunotherapy alone.

The purpose is to determine whether adding the new drug helps keep the cancer under control for a longer time. Participants receive the assigned treatment by intravenous infusion (medicine delivered through a vein) and have regular check‑ups, scans, and laboratory tests to monitor the cancer and overall health. The study continues until the disease progresses, the treatment is stopped, or the planned follow‑up period ends.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization

    After you join the study, you are randomly assigned to one of two treatment groups. This process is called randomization and ensures that the groups are comparable.

    The assignment determines whether you will receive the combination of mocertatug rezetecan with an immune checkpoint inhibitor, or the immune checkpoint inhibitor alone.

  2. Step 2

    Baseline Assessments

    Before any medication is given, you undergo a series of baseline tests. These typically include a physical examination, blood tests, and imaging studies to document the current status of your cancer.

    The results provide a reference point for evaluating how you respond to the study treatment.

  3. Step 3

    Start of Maintenance Therapy

    On the first day of treatment, you receive an intravenous (IV) infusion of the assigned medication(s).

    If you are in the combination arm, the infusion contains mocertatug rezetecan together with either pembrolizumab or dostarlimab. If you are in the control arm, you receive only pembrolizumab or dostarlimab.

    All drugs are administered as a solution for infusion directly into a vein.

  4. Step 4

    Regular Infusion Schedule

    You continue to receive the IV infusion at regular intervals that are specified by the study protocol. The exact timing (for example, every few weeks) is determined by the investigators and is the same for all participants in each arm.

    The dose of each medication is set according to the study guidelines; specific milligram amounts are not disclosed in the public information.

  5. Step 5

    Ongoing Monitoring Visits

    During the treatment period, you attend scheduled clinic visits. At each visit, you undergo safety assessments such as blood tests, vital‑sign checks, and possibly an electrocardiogram (ECG).

    Imaging studies are performed periodically to evaluate whether the cancer is stable, shrinking, or growing.

    You may also complete questionnaires that measure quality of life and symptom changes.

  6. Step 6

    Continuation or Discontinuation of Treatment

    Treatment continues until one of the following occurs: the cancer shows documented progression, you experience side effects that are deemed unacceptable, or the study reaches its planned end.

    If the treatment is stopped for any reason, you will continue to be followed for safety and outcome assessments as part of the study.

Who can join the trial?

15 criteria

  • Must be at least 18 years old and legally able to give consent.
  • Must have an ECOG performance status of 0 or 1 (fully active or able to do light work).
  • Must have adequate organ function, meaning blood tests show the kidneys, liver and other organs are working well.
  • Must have finished first‑line (induction) therapy that included platinum‑based chemotherapy (drugs such as carboplatin and paclitaxel) together with an immune checkpoint inhibitor (either pembrolizumab or dostarlimab). If chemotherapy stopped early because of side effects, at least 4 cycles are allowed, but at least 12 weeks of the immune drug must have been given.
  • Must be considered suitable to continue with maintenance immune checkpoint therapy (dostarlimab or pembrolizumab) after induction.
  • Must show no sign of cancer getting worse on scans or clinical exam after the last dose of induction therapy.
  • Must be able to start the study treatment (day 1 of cycle 1) between 3 and 9 weeks after the final dose of first‑line therapy.
  • Must have a tumor that has been confirmed by pathology as endometrial cancer (including endometrioid, serous, clear cell, carcinosarcoma, or mixed types).
  • Must meet one of the disease‑stage conditions: newly diagnosed stage III with measurable leftover tumor > 1 cm after surgery, or stage III not suitable for surgery with measurable disease, or stage IV with any leftover disease, or recurrent disease either never treated before or returning more than 12 months after previous therapy.
  • Must have a tumor that is either MMR‑proficient (MMRp) or microsatellite stable (MSS). This is checked by lab tests that look for four proteins (MLH1, MSH2, MSH6, PMS2) or by DNA testing.
  • Must provide a formalin‑fixed, paraffin‑embedded (FFPE) tumor tissue sample that is enough for central testing of B7‑H4 expression and, if needed, MMR status. The sample should come from the most recent surgery or biopsy and not from previously irradiated tissue.
  • Must agree to use effective birth‑control methods as required by local regulations.
  • If female, must not be pregnant or breastfeeding and must meet one of the following: be post‑menopausal (no periods) or be of child‑bearing potential using a highly effective contraceptive (failure < 1 % per year) for at least 30 days before the first dose, during the study, and for at least 8 months after the last dose, and must not donate eggs during this time.
  • Must have a negative pregnancy test (urine or blood) within 24 hours before the first dose; if the urine test is unclear, a blood test must be done and a positive result excludes participation.
  • Must be able to sign an informed consent form and agree to follow all study rules.

Who cannot join the trial?

27 criteria

  • Mesenchymal tumors of the uterus (uterine sarcomas) or neuroendocrine uterine cancer – these specific uterine cancers exclude you.
  • Any serious or unstable medical problem (including infections), serious psychiatric disorder, or abnormal lab test that could affect your safety, ability to give consent, or follow the study procedures.
  • Major surgery within the last 28 days or focused radiation treatment (radiotherapy) within the last 21 days before starting the study.
  • Use of any experimental drug (investigational agent) within 30 days before the first study dose.
  • Use of strong immune‑suppressing medicines within 7 days before the first dose (low‑dose prednisone ≤ 10 mg/day, inhaled or topical steroids, and short‑term steroids for procedures are allowed).
  • Previous treatment with topoisomerase I inhibitors such as irinotecan or topotecan, related antibody‑drug conjugates, B7‑H4 targeted therapy, or immune‑checkpoint inhibitors (except first‑line use allowed by the study).
  • Receiving any live vaccine within 30 days before the first dose (COVID‑19 mRNA or adenoviral vaccines are not considered live).
  • Taking drugs that block certain transport proteins (P‑gp, BCRP, OATP1B1/1B3) within 7 days, or drugs that increase P‑gp activity within 14 days before the first dose.
  • Having a blood transfusion (red cells or platelets) or receiving colony‑stimulating factors (such as G‑CSF, GM‑CSF, or erythropoietin) within 14 days before the first dose.
  • Having HIV infection and meeting any of the following: high viral load, low CD4 count, recent changes in HIV medication, a recent HIV‑related cancer, or recent HIV‑targeted vaccine (certain stable HIV cases may still be allowed).
  • Elevated liver enzyme ALT greater than 2.5 times the normal limit (or greater than 5 times if liver metastases are present).
  • Any other cancer (besides the endometrial cancer being studied) that has progressed or required treatment within the past 36 months, except for certain skin cancers that have been completely removed and are cured.
  • Total bilirubin (a liver function test) higher than 1.5 times the normal limit (people with Gilbert’s syndrome may be included if other criteria are met).
  • Having cirrhosis or an unstable liver or bile‑duct disease (signs such as fluid in the abdomen, brain changes, clotting problems, low albumin, varices, or persistent jaundice) unless the condition is well‑controlled.
  • Positive hepatitis B surface antigen (HBsAg) unless you are on effective antiviral therapy, have undetectable HBV DNA, and test negative for hepatitis D antibody.
  • Positive hepatitis B core antibody (HBcAb) unless you have undetectable HBV DNA and a negative HBsAg test.
  • Positive hepatitis C antibody unless a follow‑up test shows no HCV RNA (meaning the infection was cleared or never active).
  • Heart electrical measurement QTc longer than 470 milliseconds.
  • History of symptomatic pericarditis within the last 6 months, or serious heart rhythm problems or major ECG abnormalities within the last 12 months (including certain heart blocks, cardiomyopathy, heart attacks, severe heart failure, etc.).
  • Active kidney problems such as infection, need for dialysis, or any significant kidney condition that could affect safety (a well‑managed kidney blockage is allowed).
  • Any prior bone‑marrow transplant (allogenic or autologous) or solid‑organ transplant.
  • Known allergy or sensitivity to any part of the study drug or its ingredients.
  • Untreated brain or central‑nervous‑system (CNS) metastases, or brain/CNS metastases that have gotten worse (stable, previously treated brain metastases are allowed after stopping steroids for at least 14 days).
  • Current or past interstitial lung disease (ILD) or non‑infectious pneumonitis (lung inflammation not caused by infection).
  • Autoimmune disease that required systemic treatment (such as steroids or other immune‑suppressing drugs) within the past 24 months (replacement hormone therapy is not counted).
  • Severe immune‑related side effects from previous immunotherapy, including grade 3 or higher immune‑mediated adverse events, serious neurological problems (e.g., myasthenia gravis, encephalitis, Guillain‑Barré syndrome), severe skin reactions (such as Stevens‑Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome), or myocarditis.
  • Ongoing side effects from prior therapy that have not improved to mild (grade 1) or back to baseline, except for hair loss, hearing loss, vitiligo, hormone problems managed with replacement therapy, or mild nerve issues.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • pembrolizumab

    is an immune‑checkpoint inhibitor that helps the body’s immune system see and attack cancer cells. In this study it is given by intravenous infusion as one of the standard immunotherapy options.

  • dostarlimab

    is another immune‑checkpoint inhibitor that works in a similar way to pembrolizumab, releasing the “brakes” on the immune system so it can target cancer. It is also administered by intravenous infusion as a standard immunotherapy choice.

  • GSK5733584

    is an experimental drug being evaluated in the trial. It comes as a powder that is mixed with liquid to create a solution for infusion. The study is testing whether this new agent can improve outcomes when used with other treatments.

  • mocertatug rezetecan

    (often called Mo‑Rez) is the investigational therapy being studied in combination with the immune‑checkpoint inhibitors. It is given by intravenous infusion and is intended to work together with the immunotherapy drugs to help keep the cancer from returning after initial treatment.

What is already known about the treatment

  • KEYTRUDA 25 mg/mL concentrate for solution for infusion

    This medication is given as an intravenous infusion, meaning it is slowly dripped into a vein. It is an approved drug used in many cancers, including certain endometrial cancers, and is described in many medical studies. It works by attaching to a protein called PD‑1 on immune cells, which helps the immune system see and attack cancer cells. It belongs to the class of medicines known as immune checkpoint inhibitors.

  • JEMPERLI 500 mg concentrate for solution for infusion

    This drug is also given by intravenous infusion, where the solution is injected slowly into a vein. It is an approved treatment for several cancers, such as endometrial cancer, and is widely reported in the medical literature. It blocks the PD‑1 protein on immune cells, allowing the body’s defenses to recognize and fight tumor cells. It is classified as an immune checkpoint inhibitor.

  • GSK5733584

    This product is supplied as a powder that is mixed with liquid and then given by intravenous infusion. It is still experimental and is being studied in clinical trials, so it is not yet approved for regular medical use. The exact way it works is still being researched, but it is intended to help the immune system target cancer cells. It is considered an investigational biologic agent.

Investigated diseases

Endometrial cancer - Endometrial cancer is a tumor that starts in the lining of the uterus. In its early stage it is confined to the uterine lining, but it can grow into the muscle wall of the uterus. Over time the cancer may spread to nearby pelvic lymph nodes or other organs such as the ovaries and lungs. When it returns after initial treatment, it is called recurrent endometrial cancer. Advanced disease refers to cancer that has spread beyond the uterus at the time of diagnosis. The disease typically progresses from local growth to regional spread and eventually to distant sites.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2025-523363-37-00Protocol code224039Estimated enrolment448 patientsSponsorGlaxosmithkline Research & Development Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.